Introduction
Rheumatoid arthritis (RA) is characterized by inflammation, synovial hyperplasia, pannus formation and progressive destruction of cartilage and bone [
1,
2]. In RA, inflammatory cytokines, chemokines, growth factors and adhesion molecules are produced by leukocytes and resident synoviocytes. These factors perpetuate chronic inflammation by the recruitment of additional inflammatory cells into the sublining region that, in turn, lead to continuous production of inflammatory mediators and enzymes, resulting in destruction of joint structures [
3‐
8]. The efficacy of treatments with tumor necrosis factor (TNF) and IL-1 inhibitors strongly support the key role of inflammatory cytokines in the pathogenesis of RA [
9,
10] and points to therapeutic approaches directed toward regulation of cytokine networks involved in RA.
Poly(ADP-ribose) polymerase (PARP)-1 is a highly conserved nuclear zinc-finger protein involved in maintenance of genomic integrity. PARP-1 detects DNA breakage generated by several genotoxic agents and synthesizes and transfers ADP ribose units (poly(ADPribosyl)ation activity) into acceptor proteins involved in the conservation of chromatin structure and DNA metabolism, modulating in this way DNA repair and cell survival [
11,
12]. Studies with PARP-1 deficient mice or with chemical inhibitors have enlarged the physiological role of this protein. In these situations, lack of PARP-1 function protects against several disorders with an inflammatory component, such as endotoxic shock [
13], streptozotocin induced diabetes [
14], chronic colitis [
15] and uveitis [
16]. Two mechanisms have been proposed to explain the role of PARP-1 in these diseases. One mechanism is related to massive PARP-1 activation induced by genotoxic injury developed during the inflammatory process. In this case, hyperactivated PARP-1 would lead to ATP depletion and cell dysfunction [
17]. The other proposed mechanism is related to a functional link between PARP-1 and inflammation-related transcription factors. Several
in vivo and
in vitro studies have demonstrated the involvement of PARP-1 in the transcriptional activation of nuclear factor (NF)κB [
13,
18,
19], but the proposed mechanisms are contradictory. There is evidence for mechanisms that are both dependent on and independent of auto-poly(ADP-ribosyl)ation function. In the first case, NFκB would be blocked by binding to PARP-1 and this union would be disrupted by PARP-1 auto-poly(ADP-ribosyl)ation [
18]. In the second case, PARP-1 would act as a transcriptional co-activator in the binding of NFκB with its target DNA sequences [
19]. Recently, it has also been reported that PARP-1 regulates other transcription factors implicated in stress/inflammation, such as AP-1, Oct-1, SP-1, YY-1 and Stat-1 [
20,
21]. Thus, in addition to its involvement in genome surveillance, PARP-1 appears to have a key role in inflammatory responses.
Here we report the impact of selective PARP-1 suppression on the collagen antibody-induced arthritis model (CAIA). This model, induced by passive immunization of mice with anti-type II collagen antibodies, allows the study of the effector phase of arthritis, where PARP-1 might be involved. We have found that the absence of PARP-1 partially reduced the severity of arthritis, likely by the impairment of IL-1β and monocyte chemotactic protein (MCP)-1 transcription in arthritic tissue. These results provide support for the contribution of PARP-1 in the progression of arthritis and open the possibility that specific inhibitors might become therapeutic tools in RA.
Materials and methods
Mice
Mice lacking PARP-1 (kindly provided by G de Murcia, CNRS, Strasbourg, France) have been described previously [
22]. The mice used in these experiments were of mixed (C57BL/6 × 129Sv) background. More than ten different breeding pairs of
parp-1+/o mice were intercrossed to generate
parp-1+/+,
parp-1+/o and
parp-1o/o mice.
Parp-1o/o mice and control matched littermates (
parp-1+/+,
parp-1+/o) were analyzed.
Genotypes were assessed by PCR of tail DNA. The mice were maintained in the mouse facility of the Facultad de Medicina de Santiago de Compostela. Animal care was in compliance with Spanish regulations on the protection of animals used for experimental and other scientific purposes (Real Decreto 223/1998). The experimental protocols were approved by the Animal Care and Use Committee of the University of Santiago de Compostela.
Collagen antibody-induced arthritis (CAIA) and clinical scoring
CAIA was induced in 6-week-old male and female mice by intravenous injection on day 0 of 3 mg/mouse of an arthritogenic cocktail of 4 monoclonal anti-type II collagen antibodies (Arthrogen, Chondrex, Redmond, WA, USA) [
23]. On day 2, mice were boosted with 50 μg of lipopolysaccharide by intraperitoneal injection. Arthritis was assessed every other day by two blinded observers until day 12, using a semi-quantitative clinical score ranging from 0 to 4: 0, no swelling; 1, slight swelling and erythema of the ankle, wrist or digits; 2, moderate swelling and erythema; 3, severe swelling and erythema; and 4, maximal inflammation with joint rigidity. The maximum possible score was 16 per mouse.
Histological analysis
Hind limbs were prepared for histology by dissecting the skin and muscle, and then sectioning knee joints. Specimens were fixed for 24 hours and demineralized in phosphate-buffered saline-0.5 M EDTA for 10 days. Knee joints were embedded in paraffin and sections were cut and stained with hematoxylin and eosin (H&E) for evaluation of inflammation. For analysis of damage to cartilage, knee sections were stained with Toluidine blue, Safranin-O and Masson trichrome following standard methodology. The sections were scored by two blinded observers. Synovial inflammation was scored on a scale of 0 to 3: 0, no inflammation; 1, slight thickening of synovial cell layer and/or some inflammatory cells in the sublining; 2, thickening of synovial lining, infiltration of the sublining; and 3, pannus formation.
Exudate was scored according to the following scale: 0, no detectable neutrophil infiltration in the synovial space; 1, mild infiltration; 2, moderate infiltration; and 3, severe infiltration.
Cartilage damage was evaluated following a scale of 0 to 3: 0, normal cartilage; 1, cartilage surface irregularities and loss of metachromasia adjacent to superficial chondrocytes; 2, fibrillation of cartilage and formation of some chondrocyte clusters, with minor loss of surface cartilage; and 3, gross cartilage abnormalities, including loss of superficial cartilage, extension of fissures close to subchondral bone, and a large number of chondrocyte clusters.
Fibroblast like synoviocytes
Fibroblast-like synoviocytes (FLSs) were isolated from parp-1+/+, parp-1+/o and parp-1o/o mice. Synovial tissue was minced and incubated with 1 mg/ml collagenase in serum-free DMEM (Gibco, Invitrogen, Barcelona, Spain) for 3 hours at 37°C. After digestion, FLSs were filtered trough a nylon cell strainer (BD Falcon, Franklin Lakes, NJ, USA), washed extensively, and cultured in DMEM supplemented with 10% v/v FCS (Gibco, Invitrogen), penicillin, streptomycin, and L-glutamine (Sigma, St Louis, MO, USA) in a humidified 5% CO2 atmosphere. After overnight culture, non-adherent cells were removed, and adherent cells were cultured in DMEM supplemented with 10% v/v FCS.
Western blot analysis
Total proteins (20 μg) were separated by 10% SDS-PAGE, transferred to a PVDF membrane (Hybond-P, Amersham Biosciences, Buckinghamshire, UK) and probed with anti-PARP-1 (VIC-5, kindly provided by G de Murcia, CNRS, Strasbourg, France) and anti-actin (Sigma) antibodies as previously described [
24]. Bound antibody was revealed with goat anti-rabbit-horseradish peroxidase (Rockland Immunochemicals Inc., Gilbertsville, PA, USA) and the blot was developed using the ECL plus detection system (Amersham Biosciences).
Quantitative reverse transcription-PCR
Total RNA was obtained from joints of
parp-1+/+ and
parp-1o/o mice on day 7 following Arthrogen injection, and from joints of
parp-1+/+ and
parp-1o/o control mice without arthritis. We used the RNeasy Kit and RNase-Free DNase Set (Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions. One microgram of total RNA was subjected to cDNA synthesis using M-MLV reverse transcriptase, random primers and RNaseOUT recombinant ribonuclease inhibitor (Invitrogen). Quantitative real-time PCR was performed in duplicate in a Chromo-4 real-time thermal cycler (MJ Research, Waltham, MA, USA), using a LightCycler DNA Master SYBR Green I kit (Roche Diagnostics, Barcelona, Spain), according to the manufacturers' protocols. The specific primers used in these reactions are listed in Table
1. Relative levels of gene expression were normalized to the β-actin gene using the comparative Ct method, where Ct is the cycle at which the amplification is initially detected. The relative amount of mRNA from the different genes was calculated using the formula 2
-ΔΔCt, where:
Table 1
Primer sets used for quantitative PCR study
IL-1β
| AACCTGCTGGTGTGTGACGTTC | CAGCACGAGGCTTTTTTGTTGT |
TNF-α
| CTACTCCCAGGTTCTCTTCAA | GCAGAGAGGAGGTTGACTTTC |
IL-6
| ACAACCACGGCCTTCCCTACTT | CACGATTTCCCAGAGAACATGTG |
MCP-1
| CCACTCACCTGCTGCTACTCAT | TGGTGATCCTCTTGTAGCCCTCC |
Ccl5
| GTCGTGTTTGTCACTCGAAGGA | TTGATGTATTCTTGAACCCACTTCTT |
iNOS
| CAGCTGGGCTGTACAAACCTT | CATTGGAAGTGAAGCGTTTCG |
COX-2
| GTGGAAAAACCTCGTCCAGA | GCTCGGCTTCCAGTATTGAG |
β-Actin | AGGTCATCACTATTGGCAACGA | CACTTCATGATGGAATTGAATGTAGTT |
ΔΔCt = [Cttarget - Ctβ-actin]WT or KO with arthritis - [Cttarget - Ctβ-actin]WT or KO controls
For wild-type (WT) and PARP-1 deficient samples without arthritis, ΔΔCt equals zero and 20 equals one. For wild-type and knockout (KO) samples with arthritis, the value of 2-ΔΔCt indicates the fold change in gene expression relative to the wild-type and knockout controls, respectively. Melting curves and agarose gel electrophoresis established the purity of the amplified band.
Determination of cytokines in mice arthritic knees
Knee joints were obtained, frozen in liquid nitrogen and homogenized in 0.5 ml ice-cold 20 mM Hepes buffer supplemented with 1 mM dithiothreitol, 0.1% v/v Triton and a protease inhibitor cocktail. After incubation for 30 minutes at 4°C, the homogenate was centrifuged for 10 minutes at 10,000 × g. Protein concentration was measured in supernatants by the Bradford method and a volume containing 100 μg of proteins was subjected to ELISA for IL-1β, TNF-α, IL-6 and MCP-1 (OptEIA ELISA Sets, BD Pharmingen), according to the manufacture's instructions.
Statistical analysis
Differences between experimental groups were assessed by ANCOVA, MANCOVA and Mann-Whitney U test. p values <0.05 were considered significant.
Discussion
Previous studies using genetically engineered animals and pharmacological inhibitors have implicated PARP-1 in the pathogenesis of several inflammatory processes [
13‐
16]. In the present report, we have investigated the impact of selective PARP-1 suppression in the CAIA model and found that absence of PARP-1 protein reduces the severity of disease, likely by the impairment of IL-1β and MCP-1 transcription in joint tissues. In the arthritis model used, disease develops in most mice strains, avoiding multiple breeding into arthritis susceptible strains. Using a suitable antibody dose, arthritis incidence rises to 100% in control animals and the clinical severity and histopathology are similar to collagen-induced arthritis and human RA. Given the involvement of PARP-1 in inflammation, we considered that it could have a role in the effector phase of arthritis; the CAIA model specifically reflects this phase.
PARP-1 deficient mice had decreased severity in clinical and histological arthritis, although the incidence of disease was similar in control and deficient mice. This is in line with its described involvement in other inflammatory diseases, but with milder effect in the case of arthritis.
PARP-1 belongs to a large family of 18 proteins, encoded by different genes and displaying a conserved catalytic domain (for reviews, see [
26,
27]). PARP-1 catalyzes 80% of cellular poly(ADPribosyl)ation and the other PARP family members, PARP-2, PARP-3, PARP-4 and Tankyrases (PARP-5 a and b), all identified in the last few years, account for the remaining 20%. Therefore, it is possible that when PARP-1 is absent from development, other PARP family members with poly(ADPribosyl)ation activity could compensate for its absence. To evaluate this possibility, we treated
parp-1o/o and
parp-1+ mice with 3,4-dihydro-5- [4-(1-piperidinyl)butoxy]-1(2
H)-isoquinolinone (DPQ), one of the new potent PARP inhibitors developed. After treatment, we found similar protection to that observed in mice lacking the
parp-1 gene (data not shown), suggesting that PARP-1 is the member of the PARP proteins involved in arthritis inflammation.
Our results contrast with the significantly reduced incidence and severity of collagen induced arthritis in mice treated with INH
2BP, a PARP inhibitor, reported by Szabo and colleagues [
28]. It is possible that INH
2BP has effects other than the inhibition of PARP function, because we did not observe such a strong effect with knockout mice, nor with the DPQ inhibitor. Nevertheless, this discordance could also be attributed to either differences in the arthritis model or differences in the inhibitors. In fact, it has been recently shown that another PARP inhibitor, PJ34, reduces the severity rather than incidence of collagen induced arthritis [
16].
IL-1β is one of the major cytokines in arthritis driving inflammation and joint destruction [
2,
4,
7]. It has been reported that systemic administration of IL-1 accelerates and exacerbates the development of murine collagen induced arthritis [
29], while IL-1 receptor antagonist-deficient mice (BALB/c background) develop chronic polyarthropathy resembling RA [
30]. MCP-1 is a potent chemoattractant for monocytes. It seems to be involved in RA pathogenesis because it has been detected in patient sera and found at increased levels in FLSs from RA patients [
31‐
33]. It has been recently reported that MCP-1 induces FLS proliferation, which is pivotal in pannus formation, and increases metalloproteinase production mediated by IL-1β [
34].
Thus, the strong reduction in IL-1β and MCP-1 production observed in PARP-1 deficient mice may account for the reduced severity of arthritis, though signals of a more widespread effect are reflected in the tendency towards the decreased expression of other inflammatory mediators, such as IL-6, iNOS and COX-2.
In contrast to what has been described in the shock endotoxic model [
13,
16], we did not find impaired TNF-α production in mice lacking PARP-1. This could indicate that the requirements of PARP-1 for transcription of inflammatory genes depend on the tissue and the nature of the inflammatory stimulus. In fact, studies with a PARP inhibitor have shown an inhibitory or neutral effect on IL-1β levels depending on the model of inflammation [
16].
Competing interests
The authors declare that they have not competing interests.
Authors' contributions
SG carried out the arthritis evolution, FLS isolation and western blot experiments and quantitative real time PCR analysis. AB carried out the breeding of mice, the arthritis evolution experiments and joint isolation. AG carried out the intravenous injections in mice, performed the statistical analysis, participated in the design of the study and revision of the manuscript. JF carried out the histological scoring. GJ participated in the design and coordination of the study and revision of the manuscript. CC conceived of the study, participated in its design and coordination and drafting of the manuscript. All authors read and approved the final manuscript.